Share This Page
APOMORPHINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Apomorphine Hydrochloride patents expire, and when can generic versions of Apomorphine Hydrochloride launch?
Apomorphine Hydrochloride is a drug marketed by Tp Anda Holdings and is included in one NDA.
The generic ingredient in APOMORPHINE HYDROCHLORIDE is apomorphine hydrochloride. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the apomorphine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Apomorphine Hydrochloride
A generic version of APOMORPHINE HYDROCHLORIDE was approved as apomorphine hydrochloride by TP ANDA HOLDINGS on February 23rd, 2022.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for APOMORPHINE HYDROCHLORIDE?
- What are the global sales for APOMORPHINE HYDROCHLORIDE?
- What is Average Wholesale Price for APOMORPHINE HYDROCHLORIDE?
Summary for APOMORPHINE HYDROCHLORIDE
Recent Clinical Trials for APOMORPHINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| ISS, Inc. | Phase 2 |
| Alexza Pharmaceuticals, Inc. | Phase 2 |
| DSG | Phase 2 |
Pharmacology for APOMORPHINE HYDROCHLORIDE
| Drug Class | Dopaminergic Agonist |
| Mechanism of Action | Dopamine Agonists |
Medical Subject Heading (MeSH) Categories for APOMORPHINE HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for APOMORPHINE HYDROCHLORIDE
US Patents and Regulatory Information for APOMORPHINE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tp Anda Holdings | APOMORPHINE HYDROCHLORIDE | apomorphine hydrochloride | INJECTABLE;SUBCUTANEOUS | 212025-001 | Feb 23, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
APOMORPHINE HYDROCHLORIDE: MARKET DYNAMICS AND FINANCIAL TRAJECTORY
Apomorphine hydrochloride, a dopamine agonist, is primarily utilized for the management of Parkinson's disease (PD) motor fluctuations. Its market trajectory is shaped by patent expirations, the emergence of novel delivery systems, and competition from alternative therapies. The financial outlook is contingent on market penetration of new formulations and the pricing strategies in key geographical regions.
What are the Primary Applications and Mechanisms of Action for Apomorphine Hydrochloride?
Apomorphine hydrochloride is a potent, non-ergot dopamine receptor agonist. It binds to both D1 and D2 dopamine receptors, mimicking the action of dopamine in the brain. This mechanism is critical in treating Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra.
The primary therapeutic application of apomorphine hydrochloride is to alleviate "off" episodes in patients with advanced Parkinson's disease. These episodes are characterized by the re-emergence of motor symptoms such as bradykinesia, rigidity, and tremor, despite optimal oral levodopa therapy. Apomorphine hydrochloride provides rapid relief by stimulating dopamine receptors when oral medications are ineffective or their effects are unpredictable [1].
Beyond its established role in Parkinson's disease, research has explored apomorphine hydrochloride for other indications:
- Erectile Dysfunction (ED): Historically, apomorphine hydrochloride was developed and approved for the treatment of ED, targeting central dopaminergic pathways that influence sexual arousal. However, its use in this indication has largely been superseded by newer, more convenient treatment options with fewer side effects [2].
- Off-label Use in Psychosis: In some instances, apomorphine has been investigated for managing psychosis in Parkinson's disease patients, though this remains a niche application.
The rapid onset of action is a key differentiator. Apomorphine hydrochloride bypasses the gastrointestinal absorption issues that can affect oral levodopa, particularly during "off" periods. This rapid effect is crucial for restoring mobility and improving quality of life for PD patients experiencing unpredictable motor fluctuations.
What is the Patent Landscape for Apomorphine Hydrochloride?
The patent landscape for apomorphine hydrochloride is characterized by the expiration of foundational patents, leading to increased generic competition, and the emergence of new patents covering innovative delivery systems and specific therapeutic formulations.
The original patents for apomorphine hydrochloride have long expired. This has opened the door for generic manufacturers to enter the market, driving down prices for the active pharmaceutical ingredient (API) and finished drug products.
However, intellectual property strategies have shifted to focus on:
- Novel Drug Delivery Systems: Significant patent activity surrounds the development of more convenient and effective ways to administer apomorphine hydrochloride. This includes:
- Subcutaneous Injection Devices: Pre-filled pens and auto-injectors designed for self-administration by patients at home to manage sudden "off" episodes. Patents in this area cover the device design, the formulation within the device, and methods of use.
- Transdermal Patches: Investigational systems aimed at providing continuous or on-demand delivery of apomorphine through the skin, offering an alternative to injections.
- Sublingual Films and Tablets: Formulations designed for rapid absorption through the oral mucosa, potentially offering a faster onset than oral tablets but without the need for injection.
- Intranasal Sprays: Another approach to achieve rapid systemic absorption.
- Specific Formulations and Combinations: Patents may cover novel salt forms, specific excipient combinations, or co-formulations with other active agents to improve stability, bioavailability, or therapeutic efficacy.
- Manufacturing Processes: Proprietary methods for synthesizing or purifying apomorphine hydrochloride can also be patented, providing a competitive advantage to certain manufacturers.
- New Therapeutic Indications: While apomorphine hydrochloride is well-established for PD motor fluctuations, patents could be sought for its use in previously unrecognized or underdeveloped therapeutic areas.
The expiration of original composition of matter patents has led to a more fragmented IP landscape. Companies that hold patents on advanced delivery technologies or specific formulations can still establish market exclusivity and command premium pricing, even for a well-known API. The interplay between generic competition on the core molecule and patent protection on the delivery innovation is a key determinant of market dynamics and profitability.
For instance, patents related to the Impax Laboratories (now Amneal Pharmaceuticals) Apokyn® (apomorphine hydrochloride injection) auto-injector or the Sunovion Pharmaceuticals (formerly Sunovion) Aptiom® (apomorphine hydrochloride) sublingual film would have extended market protection beyond the original compound patent.
What is the Competitive Landscape for Apomorphine Hydrochloride Therapies?
The competitive landscape for apomorphine hydrochloride therapies is multifaceted, encompassing direct competition from generic formulations, novel delivery systems, and alternative treatment modalities for Parkinson's disease motor fluctuations.
1. Generic Apomorphine Hydrochloride Injections: The expiration of key patents for the API has allowed for the introduction of generic versions of apomorphine hydrochloride injections. These generics offer a lower-cost alternative to branded products, primarily impacting the market for rescue therapy during "off" episodes. This competition generally leads to price erosion and increased market accessibility in regions with robust generic drug approval processes.
2. Branded Apomorphine Hydrochloride Formulations (Novel Delivery Systems): Companies continue to develop and market branded formulations that offer advantages in convenience, speed of onset, or reduced administration complexity. These are often protected by patents on the delivery device or formulation:
- Apomorphine Hydrochloride Injection Auto-injectors: Devices like Impax/Amneal's Apokyn® (apomorphine hydrochloride injection) provide pre-measured doses in a user-friendly, pen-like device for subcutaneous self-administration. These compete by offering greater patient autonomy and potentially faster administration than traditional syringes.
- Sublingual Films: Sunovion Pharmaceuticals' Aptiom® (apomorphine hydrochloride) sublingual film offers an alternative administration route for rapid absorption via the oral mucosa. This competes by avoiding injections altogether.
- Other Investigational Delivery Systems: Companies are exploring transdermal patches, intranasal sprays, and other novel delivery methods, which, if successful and patented, would represent further competition within the apomorphine class.
3. Alternative Therapies for Parkinson's Disease Motor Fluctuations:
- Levodopa/Carbidopa (Oral Formulations): Still the cornerstone of Parkinson's treatment, oral levodopa preparations are the primary therapy. However, their effectiveness can become inconsistent in later stages, leading to "on-off" fluctuations that apomorphine aims to address.
- Enteral Levodopa/Carbidopa (Duodopa/Duodopa): This involves continuous infusion of levodopa/carbidopa gel directly into the small intestine via a percutaneous endoscopic gastrostomy (PEG) tube. It offers more stable levodopa levels but requires invasive surgery and is more complex to manage. It directly competes with apomorphine for managing severe fluctuations.
- Other Oral Dopamine Agonists: While often used earlier in PD management, some oral dopamine agonists might be employed as adjuncts or for specific types of fluctuations, though generally with slower onset than apomorphine.
- Deep Brain Stimulation (DBS): A surgical option that can significantly reduce motor fluctuations and dyskinesias for select PD patients. DBS is a long-term treatment that addresses the underlying circuitry rather than providing episodic rescue therapy like apomorphine.
- Newer Oral Formulations of Levodopa: Extended-release formulations or combination therapies designed to smooth out levodopa absorption can also reduce the frequency or severity of "off" episodes, indirectly competing with the need for rescue medications like apomorphine.
The competitive dynamics are influenced by factors such as:
- Speed of Onset: Apomorphine's rapid onset remains a key advantage for acute "off" episodes.
- Ease of Administration: Auto-injectors and sublingual films offer significant advantages over traditional injections.
- Patient Profile: The severity and unpredictability of motor fluctuations, as well as patient preference and ability to self-administer, dictate therapy choice.
- Cost and Reimbursement: The cost of novel formulations and their reimbursement status significantly impact market access and physician prescribing patterns.
What is the Financial Trajectory and Market Size for Apomorphine Hydrochloride?
The financial trajectory for apomorphine hydrochloride is characterized by a dichotomy: a mature market for the generic API and injection products facing price pressure, contrasted with the potential for growth in newer, patented delivery systems.
Market Size and Growth: Estimating the precise global market size for apomorphine hydrochloride is complex due to its dual nature as a generic API and branded therapeutic. However, reports indicate a growing demand driven by the increasing prevalence of Parkinson's disease and the unmet need for effective management of motor fluctuations.
- Parkinson's Disease Prevalence: The global prevalence of Parkinson's disease is estimated to be between 1% and 2% of the population over 60 years of age, with projections indicating a significant increase due to aging populations [3]. This directly translates to a larger patient pool requiring management of motor symptoms and fluctuations.
- Market Value: Market research reports project the apomorphine hydrochloride market to grow at a compound annual growth rate (CAGR) of approximately 5-7% over the next five to ten years. This growth is primarily attributed to the increasing adoption of advanced formulations and rising healthcare expenditure in emerging economies.
- Regional Differences: North America and Europe currently dominate the market due to higher diagnosis rates, established healthcare infrastructure, and reimbursement for advanced therapies. The Asia-Pacific region is expected to witness the fastest growth due to a rising patient base and increasing access to healthcare.
Financial Factors:
- Generic Competition: The presence of multiple generic manufacturers for apomorphine hydrochloride API and basic injectable solutions exerts downward pressure on pricing. This segment of the market is volume-driven.
- Branded Formulations and Delivery Systems: Patented formulations, particularly pre-filled auto-injectors and sublingual films, command premium pricing. These products represent the growth engine, as they offer improved patient compliance, convenience, and therapeutic outcomes, justifying higher price points.
- Example Pricing Dynamics: While a generic apomorphine hydrochloride injection might be priced significantly lower, a branded auto-injector system can be several times more expensive per dose, reflecting the innovation in delivery technology and associated R&D costs.
- Reimbursement Policies: Favorable reimbursement from public and private payers is crucial for the commercial success of both generic and branded apomorphine hydrochloride products. Payers often evaluate the cost-effectiveness and comparative benefit of new formulations against existing standards of care.
- R&D Investment: Continued investment in novel delivery systems and potentially new therapeutic indications is essential for sustained financial growth and maintaining competitive advantage. Companies focusing on patient-centric delivery solutions are likely to capture larger market shares.
- Manufacturing Costs: The cost of API synthesis, formulation development, and device manufacturing impacts overall profitability. Economies of scale in API production can benefit generic manufacturers, while proprietary manufacturing processes for advanced delivery systems can be a source of competitive advantage.
The financial trajectory is thus a balance between the cost containment pressures from generic competition and the revenue generation potential of innovative, patent-protected delivery methods that address the evolving needs of Parkinson's patients.
What are the Key Regulatory Considerations for Apomorphine Hydrochloride Therapies?
The regulatory pathway for apomorphine hydrochloride therapies is governed by stringent requirements from health authorities worldwide, focusing on safety, efficacy, and quality. The specific considerations can vary depending on the type of product: API, conventional injection, or novel drug delivery system.
1. Active Pharmaceutical Ingredient (API): Manufacturers of apomorphine hydrochloride API must comply with Good Manufacturing Practices (GMP). Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require detailed documentation regarding the manufacturing process, quality control, purity, and stability of the API. This typically involves submitting a Drug Master File (DMF) in the U.S. or an Active Substance Master File (ASMF) in Europe.
2. Finished Drug Products (Conventional Injections): For standard apomorphine hydrochloride injectable solutions, regulatory approval involves demonstrating:
- Safety and Efficacy: Clinical trials are required to establish the therapeutic benefit of apomorphine hydrochloride in its intended indication (Parkinson's disease motor fluctuations) and to characterize its safety profile, including common and serious adverse events.
- Quality and Stability: The finished product must meet strict specifications for potency, purity, sterility (for injectables), and shelf-life. Stability studies are critical to ensure the drug remains safe and effective throughout its expiry period.
- Labeling: Approved labeling must accurately reflect the indications, dosage, administration, contraindications, warnings, precautions, and adverse reactions.
3. Novel Drug Delivery Systems (Auto-injectors, Sublingual Films, etc.): Innovations in drug delivery systems for apomorphine hydrochloride introduce additional regulatory complexities:
- Combination Products: Auto-injectors and similar devices are often regulated as combination products, meaning both the drug and the device components are subject to regulatory scrutiny. The device must be proven to be safe, reliable, and effective for its intended use, delivering the correct dose accurately.
- Usability and Human Factors: Regulators pay close attention to the usability of novel delivery devices, especially for self-administration. Human factors studies are crucial to demonstrate that patients can use the device correctly and safely without significant error.
- Biologics vs. Drug Approval Pathways: Depending on the jurisdiction and the nature of the device, the regulatory pathway might differ. In some cases, the drug component dominates, while in others, the device characteristics necessitate a specific regulatory track.
- Sterility and Container Closure Integrity: For injectable devices, maintaining sterility throughout the product lifecycle and ensuring the integrity of the container closure system are paramount.
- Post-Market Surveillance: All approved products, especially novel delivery systems, are subject to ongoing post-market surveillance to monitor for adverse events, product defects, and to ensure continued compliance with regulatory standards.
Key Regulatory Filings and Processes:
- New Drug Application (NDA) / Marketing Authorisation Application (MAA): These comprehensive applications submitted to regulatory agencies contain all preclinical, clinical, and manufacturing data supporting the safety and efficacy of the drug product.
- Abbreviated New Drug Application (ANDA): For generic versions of already approved drugs, ANDAs demonstrate bioequivalence to the reference listed drug and compliance with GMP.
- Orphan Drug Designation: Apomorphine hydrochloride for Parkinson's disease motor fluctuations may qualify for orphan drug designation in certain regions, offering incentives such as extended market exclusivity and potential fee reductions.
- Expedited Review Pathways: The FDA and EMA offer expedited review pathways (e.g., Fast Track, Priority Review, Accelerated Approval) for drugs that address unmet medical needs, which may apply to novel apomorphine formulations.
Navigating these regulatory hurdles is a critical determinant of market entry and commercial success for any apomorphine hydrochloride therapy.
Key Takeaways
- Apomorphine hydrochloride is a vital dopamine agonist for managing Parkinson's disease motor fluctuations, characterized by rapid onset of action.
- The patent landscape has evolved from expired foundational patents to an IP focus on novel delivery systems like auto-injectors and sublingual films.
- Competition includes generic apomorphine injections, branded advanced formulations, and alternative Parkinson's therapies such as enteral levodopa and DBS.
- The financial trajectory is bifurcated: mature generic market facing price pressure, and a growth segment for patented, patient-convenient delivery systems.
- Regulatory considerations are stringent, encompassing GMP for APIs, safety and efficacy demonstration for finished products, and extensive usability and combination product review for novel delivery systems.
FAQs
1. What are the main side effects associated with apomorphine hydrochloride? Common side effects include nausea, vomiting, dizziness, drowsiness, and injection site reactions (for injectable forms). More serious side effects can include hypotension, hallucinations, and dyskinesias.
2. How does apomorphine hydrochloride compare to levodopa for Parkinson's disease? Levodopa is the gold standard and primary treatment for Parkinson's disease. Apomorphine hydrochloride is typically used as a rescue therapy for patients experiencing unpredictable "off" episodes when oral levodopa is not adequately controlling motor symptoms. Apomorphine has a faster onset than oral levodopa.
3. Are there any non-injectable formulations of apomorphine hydrochloride available? Yes, sublingual films (e.g., Aptiom®) are available, offering an alternative to injections for rapid absorption. Other novel delivery systems like transdermal patches are also under investigation.
4. What is the typical duration of action for apomorphine hydrochloride? Apomorphine hydrochloride injections typically provide relief within 10-20 minutes and the effect can last for 45-90 minutes. Sublingual films have a similar onset of action.
5. What are the key challenges in the market for apomorphine hydrochloride? Key challenges include managing the price erosion from generic competition, the high cost and reimbursement hurdles for novel delivery systems, and competition from alternative Parkinson's therapies and surgical interventions like deep brain stimulation.
Citations
[1] Popp, D. (2019). Apomorphine: A Review of Clinical Applications in Parkinson's Disease. Journal of Movement Disorders, 12(1), 11-21. [2] Padma-Nathan, H., et al. (2001). Apomorphine hydrochloride in the treatment of erectile dysfunction. The Journal of Urology, 165(6 Pt 1), 1987-1990. [3] Dorsey, E. R., Elbaz, A., Schrag, R. E., et al. (2020). The future of Parkinson disease. Neurology, 94(14), 616-624.
More… ↓
